Investor Home

Corporate Profile

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$93.87

 0.88 (0.95%)

12/14/17  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting - December 11, 2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage... Read More
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting - December 9, 2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts